BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1009 related articles for article (PubMed ID: 21296333)

  • 1. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial).
    Page RL; Connolly SJ; Crijns HJ; van Eickels M; Gaudin C; Torp-Pedersen C; Hohnloser SH;
    Am J Cardiol; 2011 Apr; 107(7):1019-22. PubMed ID: 21296333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter.
    Connolly SJ; Crijns HJ; Torp-Pedersen C; van Eickels M; Gaudin C; Page RL; Hohnloser SH;
    Circulation; 2009 Sep; 120(13):1174-80. PubMed ID: 19752319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
    Singh BN; Connolly SJ; Crijns HJ; Roy D; Kowey PR; Capucci A; Radzik D; Aliot EM; Hohnloser SH;
    N Engl J Med; 2007 Sep; 357(10):987-99. PubMed ID: 17804843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of dronedarone: a review of randomized trials.
    Christiansen CB; Torp-Pedersen C; Køber L
    Expert Opin Drug Saf; 2010 Jan; 9(1):189-99. PubMed ID: 20001756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter.
    Hohnloser SH; Connolly SJ; Crijns HJ; Page RL; Seiz W; Torp-Petersen C
    J Cardiovasc Electrophysiol; 2008 Jan; 19(1):69-73. PubMed ID: 18031520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Celivarone for maintenance of sinus rhythm and conversion of atrial fibrillation/flutter.
    Khitri AR; Aliot EM; Capucci A; Connolly SJ; Crijns H; Hohnloser SH; Kulakowski P; Roy D; Radzik D; Kowey PR
    J Cardiovasc Electrophysiol; 2012 May; 23(5):462-72. PubMed ID: 22171925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the appropriate and inappropriate use of dronedarone: lessons learned from controlled studies and regulatory submission.
    Naccarelli GV; Wolbrette DL; Samii S; Banchs JE; Penny-Peterson E; Gonzalez MD
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4 Suppl):24S-30S. PubMed ID: 21098416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials.
    Duray GZ; Schmitt J; Hohnloser SH
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4 Suppl):19S-23S. PubMed ID: 20472812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of dronedarone in patients with a prior ablation for atrial fibrillation/flutter: Insights from the ATHENA study.
    Vamos M; Calkins H; Kowey PR; Torp-Pedersen CT; Corp Dit Genti V; Wieloch M; Koren A; Hohnloser SH
    Clin Cardiol; 2020 Mar; 43(3):291-297. PubMed ID: 31872901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of potential cost savings associated with reduced rates of cardiovascular hospitalization among atrial fibrillation/flutter patients treated with dronedarone in the ATHENA trial.
    Reynolds MR; Lin J; Jhaveri M; Mozaffari E; Plich A
    Am J Ther; 2014; 21(6):500-8. PubMed ID: 23344106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.
    Gillis AM; Verma A; Talajic M; Nattel S; Dorian P;
    Can J Cardiol; 2011; 27(1):47-59. PubMed ID: 21329862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dronedarone: an emerging agent with rhythm- and rate-controlling effects.
    Wegener FT; Ehrlich JR; Hohnloser SH
    J Cardiovasc Electrophysiol; 2006 Sep; 17 Suppl 2():S17-20. PubMed ID: 16939434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study.
    Le Heuzey JY; De Ferrari GM; Radzik D; Santini M; Zhu J; Davy JM
    J Cardiovasc Electrophysiol; 2010 Jun; 21(6):597-605. PubMed ID: 20384650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study.
    Davy JM; Herold M; Hoglund C; Timmermans A; Alings A; Radzik D; Van Kempen L;
    Am Heart J; 2008 Sep; 156(3):527.e1-9. PubMed ID: 18760136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation.
    Piccini JP; Hasselblad V; Peterson ED; Washam JB; Califf RM; Kong DF
    J Am Coll Cardiol; 2009 Sep; 54(12):1089-95. PubMed ID: 19744618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dronedarone treatment following cardioversion in patients with atrial fibrillation/flutter: A post hoc analysis of the EURIDIS and ADONIS trials.
    Thind M; Crijns HJ; Naccarelli GV; Reiffel JA; Corp Dit Genti V; Wieloch M; Koren A; Kowey PR
    J Cardiovasc Electrophysiol; 2020 May; 31(5):1022-1030. PubMed ID: 32083368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States.
    Naccarelli GV; Johnston SS; Lin J; Patel PP; Schulman KL
    Clin Cardiol; 2010 May; 33(5):270-9. PubMed ID: 20513065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of dronedarone treatment on healthcare resource utilization in patients with atrial fibrillation/flutter.
    Kim MH; Lin J; Jhaveri M; Koren A
    Adv Ther; 2014 Mar; 31(3):318-32. PubMed ID: 24595638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of dronedarone vs. placebo on atrial fibrillation progression: a post hoc analysis from ATHENA trial.
    Blomström-Lundqvist C; Naccarelli GV; McKindley DS; Bigot G; Wieloch M; Hohnloser SH
    Europace; 2023 Mar; 25(3):845-854. PubMed ID: 36758013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dronedarone: current evidence and future questions.
    Schafer JA; Kjesbo NK; Gleason PP
    Cardiovasc Ther; 2010; 28(1):38-47. PubMed ID: 20074258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.